Horti_2015_Biochem.Pharmacol_97(4)_566

The alpha-7 subtype of the nicotinic acetylcholine receptor (alpha7-nAChR) is fundamental to physiology; it mediates various brain functions and represents an important target for drug discovery. Exploration of the brain nicotinic acetylcholine receptors (nAChRs) using positron-emission tomography (PET) will make it possible to better understand the important role of this receptor and to study its involvement in schizophrenia, bipolar disorder, Alzheimer's and Parkinson's diseases, drug dependence, inflammation and many other disorders and simplify the development of nicotinic drugs for treatment of these disorders. Until recently, PET imaging of alpha7-nAChRs has been impeded by the absence of good radiotracers. This review describes various endeavors to develop alpha7-nAChR PET tracers by several research groups including the author's group. Most initial PET tracers for imaging alpha7-nAChRs did not exhibit suitable imaging properties due to their low specific binding. Newly discovered [(18)F]ASEM is the first highly specific alpha7-nAChR radioligand and in 2014 it was translated to human PET imaging.